Evidence report on acute migraine treatments. This report will serve as the basis for discussion during a public meeting on January 23, 2020.View More on this Topic
ICER’s final report on JAK inhibitors for rheumatoid arthritis, including a summary of the public meeting and key policy recommendations.View More on this Topic
ICER’s final assessment and report.
NOTE: After initial publication of the Unsupported Price Increase Report, Genentech provided ICER with exact values for the net price of Rituxan in Q42016 and Q42018, and the volume sold in 2017 and 2018. Due to the discrepancy between the exact values and the data ICER obtained from SSR Health, LLC, ICER decided to update the report with the data provided by Genentech.
View More on this Topic